All medications come from licensed 503A compounding pharmacies and are available without insurance or membership fees
Liraglutide and Semaglutide, a weekly GLP- 1 receptor agonist, was finally approved for both indications
Excess weight is a risk factor for chronic kidney disease (CKD), as obesity is linked to conditions like Type 2 diabetes and high blood pressure, which can harm your kidneys
doi: 10.1186/s12887-022-03768-3 540 MengfanFZhangCLiuBLiuSShiDLiuJet al
For diabetes treatment context, the American Diabetes Association Standards of Care outline evidence-based approaches to type 2 diabetes management
Signs you're ready to move to the next dose: GI symptoms (nausea, vomiting, diarrhea) have resolved or are minimal for at least 7 consecutive days Appetite suppression remains noticeable but you sense a plateau effect developing at the current dose You have completed at least 4 full weeks at the current dose level You have no significant intercurrent illness that might confuse attribution of new symptoms Signs to wait: Ongoing nausea or vomiting, even if mild, at the end of the current dose phase A recent GI illness (unrelated to the medication) that makes it hard to attribute current symptoms A major life stressor or schedule disruption that might amplify side effects Fewer than 4 weeks at the current dose, regardless of how you feel When in doubt, an additional week at the current dose costs very little